Xencor Business Summary

Xencor Inc (XNCR) is a clinical-stage biopharmaceutical company that generates revenue through a hybrid model of technology licensing, strategic collaborations, and royalty streams from marketed products. The company’s primary business segments are centered on its proprietary XmAb® protein engineering platform, which facilitates the development of engineered antibodies and cytokines for oncology and autoimmune diseases. Revenue is driven by milestone payments and royalties from high-profile partnerships, such as those with Incyte for Monjuvi® and Alexion for Ultomiris®, the latter of which recently saw a patent extension into 2028. Xencor’s internal pipeline focuses on bispecific T-cell engagers, such as XmAb819 for renal cell carcinoma, and immunology candidates like XmAb942 for inflammatory bowel disease. In the competitive landscape, Xencor contends with specialized antibody engineering firms such as Macrogenics, Zymeworks, and AnaptysBio, as well as large-cap biopharma like Regeneron. Xencor distinguishes itself as a platform-centric innovator that balances a robust wholly owned pipeline with broad industry-wide adoption of its Fc-engineering technology. The company was co-founded in 1997 by Dr. Bassil Dahiyat and Dr. Stephen Mayo, leveraging foundational protein design research from the California Institute of Technology. Dr. Dahiyat, a pioneer in computational protein engineering with a Ph.D. from Caltech, continues to lead as President and CEO. The technical leadership is anchored by Executive VP and Chief Scientific Officer Dr. John R. Desjarlais, a biophysics expert from Johns Hopkins University who oversees the XmAb platform's evolution. Other key executives include CFO Bart Cornelissen and SVP of Clinical Development Mark Osterman, who joined in late 2025 from Bristol Myers Squibb to spearhead the autoimmune portfolio. Xencor’s board features notable industry veterans like Dr. Raymond Deshaies, a former Senior VP of Global Research at Amgen, and Dr. Barbara Klencke. The company maintains a strong institutional investor base, with significant holdings from The Vanguard Group, BlackRock, and Renaissance Technologies.